US FDA Orphan Exclusivity Would Revert To Pre-Catalyst Status Under Senate Legislation

Federal court decision said the FDA cannot grant orphan exclusivity for subpopulations of a disease, which agency officials fear could damage pediatric rare disease drug development.

Drugs and judge's gavel
A court ruling denies FDA from awarding orphan exclusivity for population subsets, such as adults or children. • Source: Shutterstock

Catalyst Pharmaceuticals, Inc.’s court victory, which scrambled the US Food and Drug Administration’s orphan drug exclusivity policy, could be undone in upcoming user fee reauthorization legislation.

A federal appeals court in September 2021 ruled that the FDA should withdraw approval of Jacobus Pharmaceutical Co. Inc’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Rare Diseases

More from Pink Sheet